TEVA Statistics

Total Valuation

Teva Pharmaceutical Industries has a market cap or net worth of ILS 77.40 billion. The enterprise value is 140.88 billion.

Market Cap	77.40B
Enterprise Value	140.88B

Important Dates

The next estimated earnings date is Wednesday, November 6, 2024.

Earnings Date	Nov 6, 2024
Ex-Dividend Date	n/a

Share Statistics

Shares Outstanding	n/a
Shares Change (YoY)	+0.85%
Shares Change (QoQ)	+0.89%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.13B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.97, with an EV/FCF ratio of 55.11.

EV / Earnings	-82.60
EV / Sales	2.30
EV / EBITDA	7.97
EV / EBIT	10.74
EV / FCF	55.11

Financial Position

The company has a current ratio of 0.89, with a Debt / Equity ratio of 2.88.

Current Ratio	0.89
Quick Ratio	0.46
Debt / Equity	2.88
Debt / EBITDA	4.03
Debt / FCF	27.87
Interest Coverage	3.40

Financial Efficiency

Return on equity (ROE) is -10.51% and return on invested capital (ROIC) is 8.04%.

Return on Equity (ROE)	-10.51%
Return on Assets (ROA)	5.16%
Return on Capital (ROIC)	8.04%
Revenue Per Employee	1.72M
Profits Per Employee	-47,726
Employee Count	36,472
Asset Turnover	0.39
Inventory Turnover	2.05

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +90.68% in the last 52 weeks. The beta is 0.88, so Teva Pharmaceutical Industries's price volatility has been lower than the market average.

Beta (5Y)	0.88
52-Week Price Change	+90.68%
50-Day Moving Average	6,657.60
200-Day Moving Average	5,313.33
Relative Strength Index (RSI)	53.96
Average Volume (20 Days)	871,181

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.14

Income Statement

In the last 12 months, Teva Pharmaceutical Industries had revenue of ILS 61.33 billion and -1.71 billion in losses. Loss per share was -1.52.

Revenue	61.33B
Gross Profit	30.36B
Operating Income	13.12B
Pretax Income	-542.17M
Net Income	-1.71B
EBITDA	17.19B
EBIT	13.12B
Loss Per Share	-1.52

Full Income Statement

Balance Sheet

The company has 8.50 billion in cash and 71.24 billion in debt, giving a net cash position of -62.74 billion.

Cash & Cash Equivalents	8.50B
Total Debt	71.24B
Net Cash	-62.74B
Net Cash Per Share	n/a
Equity (Book Value)	24.71B
Book Value Per Share	21.13
Working Capital	-5.29B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.40 billion and capital expenditures -1.84 billion, giving a free cash flow of 2.56 billion.

Operating Cash Flow	4.40B
Capital Expenditures	-1.84B
Free Cash Flow	2.56B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 49.50%, with operating and profit margins of 21.39% and -2.78%.

Gross Margin	49.50%
Operating Margin	21.39%
Pretax Margin	-0.88%
Profit Margin	-2.78%
EBITDA Margin	28.02%
EBIT Margin	21.39%
FCF Margin	4.17%

Dividends & Yields

Teva Pharmaceutical Industries does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.85%
Shareholder Yield	-0.85%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on June 27, 2004. It was a forward split with a ratio of 2.

Last Split Date	Jun 27, 2004
Split Type	Forward
Split Ratio	2

Scores

Teva Pharmaceutical Industries has an Altman Z-Score of 0.37. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.37
Piotroski F-Score	n/a